Glucotrack (Nasdaq:GCTK) announced today that it plans to expand its glucose monitoring technology to measure glucose in the epidural space. Rutherford, New Jersey-based Glucotrack said CGM taking readings in the spinal epidural space could … [Read More...] about Glucotrack expands CGM tech to spinal epidural space
Main Content
Drug Tech
Today on Drug Delivery Business
- Kindeva Drug Delivery has a new COO
- Fresenius Kabi has a Class I recall of Ivenix Infusion System software
- Ypsomed, ten23 health collab on YpsoDose patch injector
- Glucotrack expands CGM tech to spinal epidural space
- RenovoRx raises $11.1M to support oncology drug delivery trial
- Cook Medical wins DOD contract for drug-eluting stents
- Dexcom, MD Revolution partner to integrate CGM into remote care platform
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
Kindeva Drug Delivery has a new COO
By Sean Whooley
Kindeva Drug Delivery announced today that it appointed Denis Johnson as its new chief operating officer (COO). Johnson's responsibilities include leading global operations for Kindeva's manufacturing and R&D facilities across the U.S. and UK. … [Read More...] about Kindeva Drug Delivery has a new COO
Fresenius Kabi has a Class I recall of Ivenix Infusion System software
The FDA this week labeled Fresenius Kabi’s recall of some Ivenix Infusion Systems (IIS) as Class I, the most serious kind. Fresenius Kabi USA issued the recall of Ivenix Infusion System LVP software, its infusion pump software, due to an issue of … [Read More...] about Fresenius Kabi has a Class I recall of Ivenix Infusion System software
Ypsomed, ten23 health collab on YpsoDose patch injector
By Sean Whooley
Ypsomed announced today that it entered into a partnership with ten23 health to commercialize its YpsoDose wearable injector. Burgdorf, Switzerland-based Ypsomed designed YpsoDose for the subcutaneous self-injection of large-volume doses. ten23 … [Read More...] about Ypsomed, ten23 health collab on YpsoDose patch injector
Glucotrack expands CGM tech to spinal epidural space
By Sean Whooley
Glucotrack (Nasdaq:GCTK) announced today that it plans to expand its glucose monitoring technology to measure glucose in the epidural space. Rutherford, New Jersey-based Glucotrack said CGM taking readings in the spinal epidural space could … [Read More...] about Glucotrack expands CGM tech to spinal epidural space
RenovoRx raises $11.1M to support oncology drug delivery trial
By Sean Whooley
RenovoRx (Nasdaq:RNXT) announced today that it closed a private placement worth gross proceeds of approximately $11.1 million. The $11.1 million adds to a separate private placement that brought in proceeds of approximately $6.1 million in … [Read More...] about RenovoRx raises $11.1M to support oncology drug delivery trial
Cook Medical wins DOD contract for drug-eluting stents
By Sean Whooley
Cook Medical announced today that the U.S. Dept. of Defense (DOD) awarded it an ECAT contract for implantable medical devices. The contract includes implantable vascular medical devices like the Zilver PTX drug-eluting peripheral stent. It also … [Read More...] about Cook Medical wins DOD contract for drug-eluting stents
Dexcom, MD Revolution partner to integrate CGM into remote care platform
By Sean Whooley
MD Revolution today announced a partnership with Dexcom (Nasdaq:DXCM) to integrate CGM into its remote care management platform. Dexcom develops continuous glucose monitoring technology (CGM), including its latest-generation G7. The system pairs … [Read More...] about Dexcom, MD Revolution partner to integrate CGM into remote care platform
OM1, Medtronic partner on drug-eluting implant study
By Sean Whooley
OM1 today announced positive results from its partnership with Medtronic (NYSE:MDT) evaluating the Propel corticosteroid-eluting implants. The Propel bioabsorbable implant family came to Medtronic through its acquisition of IntersectENT in 2022. … [Read More...] about OM1, Medtronic partner on drug-eluting implant study
Insulet applauds as UK begins artificial pancreas rollout
By Sean Whooley
Insulet (Nasdaq:PODD) expressed its excitement today as a new diabetes initiative in the UK could bring artificial pancreas' to many with diabetes. NHS England said tens of thousands of children and adults with type 1 diabetes in the country will … [Read More...] about Insulet applauds as UK begins artificial pancreas rollout
Biolinq raises $58M to support intradermal glucose sensor
By Sean Whooley
Biolinq announced today that it completed a $58 million financing to support the progression of its proprietary intradermal glucose sensor. Alpha Wave Ventures led the funding round. Niterra's corporate venture capital fund jointly operated with … [Read More...] about Biolinq raises $58M to support intradermal glucose sensor
In case you missed it
- InfuTronix has a Class I infusion pump recall
- Tandem Mobi automated insulin pump wins FDA nod for expanded pediatric use
- FDA clears Baxter Novum IQ large-volume infusion pump, Dose IQ safety software
- Tandem Diabetes Care taps miniaturization and automation for its latest systems
- Ypsomed sells pen needle, blood glucose monitor business to focus on insulin pump
- ivWatch wins FDA nod for infusion monitoring tech
- BD ups domestic syringe production in wake of FDA warnings on syringes made in China
- Insulet picks new CFO following McMillan’s move to 3M spinoff
- FDA issues warning letter to Medline over plastic syringes from China
- Medtronic is raising the bar on outcomes with MiniMed 780G automated insulin delivery system
- FDA clears automated insulin delivery system from Sequel Med Tech
- The biggest diabetes tech news out of ATTD 2024
- Ascensia, Senseonics announce new CGM cost savings
- Boston Scientific has positive Agent DCB study results
- Medtronic highlights global performance of MiniMed 780G automated insulin delivery system
Clinical Trials
Glucotrack expands CGM tech to spinal epidural space
Glucotrack (Nasdaq:GCTK) announced today that it plans to expand its glucose monitoring technology to measure glucose in the epidural space. Rutherford, New Jersey-based Glucotrack said CGM taking readings in the spinal epidural space could integrate with existing treatments for painful diabetic neuropathy (PDN). Specifically, Glucotrack sees spinal cord stimulation (SCS) technology as a potential integration […]
OM1, Medtronic partner on drug-eluting implant study
OM1 today announced positive results from its partnership with Medtronic (NYSE:MDT) evaluating the Propel corticosteroid-eluting implants. The Propel bioabsorbable implant family came to Medtronic through its acquisition of IntersectENT in 2022. OM1 and Medtronic partnered on their study to focus on healthcare resource use and long-term outcomes in patients with chronic rhinosinusitis (CRS) who underwent […]
The biggest diabetes tech news out of ATTD 2024
Catch up on the latest in diabetes tech from Dexcom, Abbott, Roche Diabetes Care, Insulet, Medtronic and Know Labs. Every year, the diabetes community comes together for the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). In this year’s 17th installment, some of the biggest names shared new studies and technologies set to […]
Medtronic highlights global performance of MiniMed 780G automated insulin delivery system
Medtronic (NYSE:MDT) shared new clinical and real-world evidence backing the use of its MiniMed 780G system around the world. Data shared at ATTD 2024 in Florence, Italy, included the largest set of data from early users in the U.S. Results built upon three-year data from more than 100,000 real-world users who outperformed international time in […]
Know Labs has positive accuracy data for non-invasive glucose monitor
Know Labs (NYSE:KNW) announced interim results highlighting the accuracy of its non-invasive glucose monitoring sensor. Seattle-based Know Labs conducted a study evaluating its proprietary radiofrequency (RF) dielectric sensor. The sensor non-invasively measured blood glucose in participants with prediabetes and type 2 diabetes. It used venous blood as a comparative reference. Know Labs reported a mean […]